The risks of ischemic and hemorrhagicstroke and poor neurological outcomes after stroke are increased in people with type 2 diabetes. Explore how to manage the hyperacute stroke stage and CV disease prevention.
Everything you need to know from EndoBridge 2023. Find out the latest developments across all aspects of endocrinology and metabolism, and learn about the clinical approaches to common endocrine issues.
STEP-HFpEF trial findings indicate that weekly semaglutide improves heart failure symptoms, physical limitations, and body weight in people with obesity-related heart failure and type 2 diabetes.
The Improving Diabetes Steering Committee outlines the place, value, and advantages of SGLT2 inhibitors in the treatment of type 2 diabetes. With user-friendly tools to support their use.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
Rapidly progressive insulin-dependent diabetes in the absence of islet autoantibodies developed 2 years after starting treatment with the immune checkpoint inhibitor nivolumab.
HC-HB is a rare movement disorder that can occur in patients with poorly controlled diabetes and hyperglycemia without ketoacidosis. The mainstay of treatment is prompt correction of hyperglycemia.
This case report considers two cases of type 1 diabetes diagnosed after multiple COVID-19 vaccinations. HLA haplotypes associated with susceptibility to type 1 diabetes were present in both cases.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Type 2 DiabetesDiabetes and Cardiovascular Disease (D Bruemmer, Section Editor)
Type 2 diabetes (T2D) is a major health care problem in the US, affecting approximately 37 million Americans or ~ 10% of the adult population, and for every person with T2D, there ~ 2 individuals with prediabetes [ 1 ]. Cardiovascular disease (CVD) …
Type 2 diabetes mellitus (T2DM) is a global health concern, and its prevalence has been steadily increasing over the years [ 1 ]. The International Diabetes Federation (IDF) estimated that approximately 537 million adults (ages 20–79) were living …
Gestational diabetes mellitus (GDM) refers to abnormal glucose tolerance detected during pregnancy in women without a history of diabetes, impacting the health of both mother and fetus [ 1 , 2 ]. Despite decades of debate on standardized screening …
One of the most common diseases in the modern era, diabetes mellitus (DM), is caused by a variety of factors, including inherited traits and environmental changes [ 1 ]. The prevalence of this chronic metabolic illness is rising as a result of the …
An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
An independent educational program featuring simulated patient consultations. Make knowledge-based decisions on diagnosis and management of CKD with and without co-morbidities, and learn from experts Kevin Fernando and David Wheeler.
Insulin therapy is a necessary step in achieving optimal glycemic targets in type 1 diabetes (T1DM), but also in most advanced patients with type 2 diabetes (T2DM) when oral antidiabetic agents and non-insulin injectable treatments have failed to …
The International Diabetes Federation (IDF) Atlas reported that in 2021, 537 million people had diabetes globally; of these, type 2 diabetes is estimated to account for over 90% of cases [ 1 , 2 ]. This number is predicted to increase by 46% to 783 …
During the recent coronavirus disease 2019 (COVID-19) pandemic, nationwide lockdowns were imposed in most countries to contain the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [ 1 – 4 ]. Patients with diabetes mellitus …
Type 1 diabetes, currently remains a non-preventable chronic disease [ 1 ] despite various ongoing research like pharmacologically enhanced regulatory hematopoietic stem cells [ 2 ] and targeted delivery of immune therapeutics using nanoparticles [ …3
The risks of ischemic and hemorrhagicstroke and poor neurological outcomes after stroke are increased in people with type 2 diabetes. Explore how to manage the hyperacute stroke stage and CV disease prevention.
The risks of ischemic and hemorrhagicstroke and poor neurological outcomes after stroke are increased in people with type 2 diabetes. Explore how to manage the hyperacute stroke stage and CV disease prevention.
Children with type 1 diabetes who are admitted to hospital can continue to receive their insulin via a home-based system while being treated as inpatients.
